Prima BioMed’s CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO

[Marketwired] – Prima BioMed Ltd announced today that the American Society of Clinical Oncology has accepted the abstract entitled, Progression-free survival in ovarian cancer patients in second remission is improved … more

View todays social media effects on PBMD

View the latest stocks trending across Twitter. Click to view dashboard

See who Prima is hiring next, click here to view